Xu Jingwen, Gewirtz David A
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Massey Cancer Center, 401 College St., Richmond, VA 23298, USA.
Biomolecules. 2022 Mar 17;12(3):463. doi: 10.3390/biom12030463.
Cisplatin has long been a first-line chemotherapeutic agent in the treatment of cancer, largely for solid tumors. During the course of the past two decades, autophagy has been identified in response to cancer treatments and almost uniformly detected in studies involving cisplatin. There has been increasing recognition of autophagy as a critical factor affecting tumor cell death and tumor chemoresistance. In this review and commentary, we introduce four mechanisms of resistance to cisplatin followed by a discussion of the factors that affect the role of autophagy in cisplatin-sensitive and resistant cells and explore the two-sided outcomes that occur when autophagy inhibitors are combined with cisplatin. Our goal is to analyze the potential for the combinatorial use of cisplatin and autophagy inhibitors in the clinic.
顺铂长期以来一直是治疗癌症的一线化疗药物，主要用于治疗实体瘤。在过去二十年中，人们发现自噬是对癌症治疗的一种反应，并且在涉及顺铂的研究中几乎都能检测到。自噬作为影响肿瘤细胞死亡和肿瘤化疗耐药性的关键因素，越来越受到人们的重视。在这篇综述和评论中，我们介绍了四种对顺铂耐药的机制，随后讨论了影响自噬在顺铂敏感和耐药细胞中作用的因素，并探讨了自噬抑制剂与顺铂联合使用时出现的双面结果。我们的目标是分析顺铂和自噬抑制剂联合用于临床的潜力。
